ArticleJournal of biosciences2018
Human cathelicidin LL-37 - Does it influence the homeostatic imbalance in mental disorders?
Article in Journal of biosciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases.Biomolecules · 2024Review
- Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.Brain, behavior, & immunity - health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to killing pathogens and influencing immunological processes, cathelicidin LL-37 is a multifunctional host defense peptide with a role in homeostasis. It has been suggested that imbalances in homeostatic signaling from inflammatory/ immune, endocrine and metabolic cascades and oxidative stress may partially contribute to the pathogenesis of mental disorders. The purpose of the study was to identify any differences in LL-37 levels between patients with schizophrenia, euthymic bipolar disorder, bacterial pneumonia, pulmonary tuberculosis, and healthy controls. Thirty-five patients with chronic paranoid schizophrenia, 40 patients with chronic, euthymic bipolar disorder, 30 patients with bacterial pneumonia, 32 patients with pulmonary tuberculosis, and 38 healthy volunteers were included in this study. The patients with schizophrenia demonstrated a significantly lower level of LL-37 than those with bipolar disorder (p=0.006) and those with pulmonary TB (p less than 0.001). Significant differences in LL-37 levels were found between patients with bipolar disorder, bacterial pneumonia (p less than 0.001) and pulmonary TB (p=0.004). Our findings suggest that changes observed in the serum level of LL-37 in psychiatric patients enrolled in this study could be a result of homeostatic imbalance.
Indexed as
Identifiers
29872020W2802325887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.